Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

PURPOSE: Lenalidomide is an oral immunomodulatory drug with multiple effects on the immune system and tumor cell microenvironment leading to inhibition of malignant cell growth. Based on encouraging reports of lenalidomide in relapsed and refractory chronic lymphocytic leukemia (CLL), we investigate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Chen, Christine I., Bergsagel, P. Leif, Paul, Harminder, Xu, Wei, Lau, Anthea, Dave, Nimisha, Kukreti, Vishal, Wei, Ellen, Leung-Hagesteijn, Chungyee, Li, Zhi Hua, Brandwein, Joseph, Pantoja, Mariela, Johnston, James, Gibson, Spencer, Hernandez, Tiffany, Spaner, David, Trudel, Suzanne
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874217/
https://ncbi.nlm.nih.gov/pubmed/21189385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.29.8133
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados